Is Amgen Inc. (AMGN) the Best Pharma Stock to Invest in Amid the Domestic Manufacturing Boom?

Noor Ul Ain Rehman

Tue, May 13, 2025, 2:01 PM 5 min read

We precocious published a database of Domestic Manufacturing Boom: 12 Best Pharma Stocks to Invest successful Now. In this article, we are going to instrumentality a look astatine wherever Amgen Inc. (NASDAQ:AMGN) stands against different champion pharma stocks to put successful present amid the home manufacturing boom.

Domestic manufacturing successful the pharmaceutical manufacture has fallen considerably successful the past decades, with astir progressive constituent accumulation moving to China and different countries. According to the Food and Drug Administration, this inclination mostly emerged owed to the debased labour costs and different factors successful the process.

According to statistic by consulting steadfast EY, the United States imported astir $203 cardinal successful pharmaceutical products successful 2023 alone. Around 73% of these imports came from Europe, chiefly Germany, Ireland, and Switzerland. However, this inclination is apt to alteration successful the future.

On May 5, CNBC reported that President Trump signed an enforcement bid incentivizing medicine cause manufacturing successful the United States. With imaginable tariffs connected imported medicines looming, the bid streamlines the process for pharmaceutical companies to physique caller accumulation sites successful the country.

Trump’s bid directed the Food and Drug Administration to streamline reviews and region unnecessary requirements to slash the clip it usually takes to o.k. manufacturing plants successful the United States. According to a White House information sheet, the bid entails moving with home drugmakers to “provide aboriginal enactment earlier facilities travel online.” CNBC reported that the bid besides directed the FDA to summation the inspection fees for overseas manufacturing plants and heighten the “enforcement of active-ingredient root reporting by overseas producers.”

The FDA’s commissioner, Marty Makary, said the bid would let the bureau to behaviour much caller manufacturing tract inspections with the aforesaid resources. The bureau would besides summation overseas cause installation inspections, going from announced to “surprise” visits. Makary said:

“We had this brainsick strategy successful the United States wherever American pharma manufacturers .. are enactment done the ringer with inspections, and the overseas sites get a batch easier with scheduled visits, portion we person astonishment visits.”

According to White House estimates, gathering caller pharmaceutical manufacturing capableness tin instrumentality 5 to 10 years, which the medication considers “unacceptable from a national-security standpoint.” President Trump said the pursuing astir the concern successful a information sheet: